PTC Therapeutics, Inc. (PTCT)
Nasdaq: PTCT · Pharmaceutical Preparations · Warren, NJ · filing with the SEC since 2004
Grade6.3
◀ Past 6.9● Present 5.8▶ Future 6.4
Who owns PTC Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 14.8% of Common Stock, as its SCHEDULE 13G/A filed Dec 4, 2025 says.
Directors and officers
18
report now, of 30 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Dec 4, 2025 · Common Stock · 8% in Apr 17, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 6% in Feb 17, 2026
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Feb 9, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Wellington Management Group LLP
SCHEDULE 13G/A · filed Feb 10, 2026 · Common Stock · reported falling below 5%, from 6.2% in Feb 10, 2025
Camber Capital Management LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock $0.001 par value per share · reported falling below 5%
Armistice Capital, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.96% in Aug 14, 2025
Toronto Dominion Bank
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.2% in Feb 13, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 10.4% in Oct 30, 2025
What PTCT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Agilis
A company bought · acquisition · Aug 2018 · owns, named in the 10-K filed Feb 19, 2026
5 subsidiaries in 2 countries, from the list filed with the 10-K filed Feb 19, 2026.
Insider tradesForm 4
206sales
0purchases
206sales on a scheduled plan
13people selling
$57.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 16, 2025 to Oct 16, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 16, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window13 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 56 | $22.4M | 56 | 0 | $0 |
| Pauwels Eric | CHIEF BUSINESS OFFICER | 28 | $7.5M | 28 | 0 | $0 |
| Schmertzler Michael | director | 20 | $6.6M | 20 | 0 | $0 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 13 | $4.2M | 13 | 0 | $0 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 52 | $4.2M | 52 | 0 | $0 |
| Reeve Emma | director | 6 | $2.5M | 6 | 0 | $0 |
| Jacobson Allan Steven | director | 10 | $2.1M | 10 | 0 | $0 |
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | 5 | $1.9M | 5 | 0 | $0 |
| Steele Glenn Jr Md Phd | director | 2 | $1.7M | 2 | 0 | $0 |
| Okey Stephanie | director | 3 | $1.5M | 3 | 0 | $0 |
| Smith Mary L. | director | 2 | $1.4M | 2 | 0 | $0 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | 6 | $1.1M | 6 | 0 | $0 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 3 | $700,000 | 3 | 0 | $0 |